Stavudine and lamivudine. two new nucleoside analogues efficient against HIV
Gerstoft, J.
Ugeskrift for Laeger 160(4): 457-461
1998
ISSN/ISBN: 0041-5782 PMID: 9463266 Document Number: 487436
Document emailed within 1 workday
Related Documents
Mcelhinney, R.S.; Mccormick, J.E.; Bibby, M.C.; Double, J.A.; Atassi, G.; Dumont, P.; Pratesi, G.; Radacic, M. 1989: Nucleoside analogues. 9. Seco-nucleoside analogues of some 5-fluorouracil/nitrosourea molecular combinations having uracil as base: synthesis and anti-tumour activity Anti-Cancer Drug Design 4(3): 191-207Cieślak, J.; Sobkowski, M.; Jankowska, J.; Wenska, M.; Szymczak, M.; Imiolczyk, B.; Zagórowska, I.; Shugar, D.; Stawiński, J.; Kraszewski, A. 2001: Nucleoside phosphate analogues of biological interest, and their synthesis via aryl nucleoside H-phosphonates as intermediates Acta Biochimica Polonica 48(2): 429-442
Hemanth Kumar, A.K.; Ramachandran, G.; Rajasekaran, S.; Padmapriyadarsini, C.; Narendran, G.; Anitha, S.; Subramanyam, S.; Kumaraswami, V.; Swaminathan, S. 2009: Pharmacokinetics of lamivudine and stavudine in generic fixed-dose combinations in HIV-1 infected adults in India Indian Journal of Medical Research 130(4): 451-457
Pensi, T. 2007: Fixed dose combination of lamivudine, stavudine and nevirapine in the treatment of pediatric HIV infection: a preliminary report Indian pediatrics 44(7): 519-521
Idigbe, E.O.; Adewole, T.A.; Eisen, G.; Kanki, P.; Odunukwe, N.N.; Onwujekwe, D.I.; Audu, R.A.; Araoyinbo, I.D.; Onyewuche, J.I.; Salu, O.B.; Adedoyin, J.A.; Musa, A.Z. 2005: Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program Journal of Acquired Immune Deficiency Syndromes 40(1): 65-69
Kiertiburanakul, S.; Khongnorasat, S.; Rattanasiri, S.; Sungkanuparph, S. 2007: Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients Journal of the Medical Association of Thailand 90(2): 237-243
Getahun, A.; Tansuphasawadikul, S.; Desakorn, V.; Dhitavat, J.; Pitisuttithum, P. 2006: Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection Journal of the Medical Association of Thailand 89(9): 1472-1478
Desakorn, V.; Karmacharya, B.Man.; Thanachartwet, V.; Kyaw, N.Lin.; Tansuphaswadikul, S.; Sahassananda, D.; Dhitavat, J.; Maek-a-nantawat, W.; Pitisuttithum, P. 2011: Effectiveness of fixed-dose combination stavudine, lamivudine and nevirapine (GPO-VIR) for treatment of naïve HIV patients in Thailand: a 3-year follow-up Southeast Asian Journal of Tropical Medicine and Public Health 42(6): 1414-1422
Poerksen, G.; Pollock, L.; Moons, P.; Chesshyre, E.; Burger, D.; Khoo, S.; Molyneux, E. 2010: Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets Antiviral Therapy 15(3): 343-350
Molina, J.M.; Chêuc, G.; Ferchal, F.; Journot, V.; Pellegrin, I.; Sombardier, M.N.; Rancinan, C.; Cotte, L.; Madelaine, I.; Debord, T.; Decazes, J.M. 1999: Results of the ALBi trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients Antiviral Therapy 4(Suppl 3): 71-74
Monif, T.; Tippabhotla, S.K.; Garg, M.; Singla, A.K.; Vijan, T. 2006: Nevirapine/lamivudine/stavudine as a combined-formulation tablet: bioequivalence study compared with each component administered concurrently under fasting condition International Journal of Clinical Pharmacology and Therapeutics 44(6): 276-283
Anekthananon, T.; Ratanasuwan, W.; Techasathit, W.; Sonjai, A.; Suwanagool, S. 2004: Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study Journal of the Medical Association of Thailand 87(7): 760-767
Manosuthi, W.; Kiertiburanakul, S.; Chaovavanich, A.; Sungkanuparph, S. 2007: Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients Journal of the Medical Association of Thailand 90(2): 244-250
Vanprapar, N.; Cressey, T.R.; Chokephaibulkit, K.; Muresan, P.; Plipat, N.; Sirisanthana, V.; Prasitsuebsai, W.; Hongsiriwan, S.; Chotpitayasunondh, T.; Eksaengsri, A.; Toye, M.; Smith, M.E.; McIntosh, K.; Capparelli, E.; Yogev, R. 2010: A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand Pediatric Infectious Disease Journal 29(10): 940-944
Beránek, J. 1986: A study on structure-activity relationships of nucleoside analogues Drugs under Experimental and Clinical Research 12(4): 355-367
Margot, N.A.; Miller, M.D. 2005: In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1 Antiviral Therapy 10(2): 343-348
Côté, H.él.èn.C.F. 2005: Possible ways nucleoside analogues can affect mitochondrial DNA content and gene expression during HIV therapy Antiviral Therapy 10(Suppl 2): M3-11
Mouroux, M.; Descamps, D.; Izopet, J.; Yvon, A.; Delaugerre, C.; Matheron, S.; Coutellier, A.; Valantin, M.A.; Bonmarchand, M.; Agut, H.; Massip, P.; Costagliola, D.; Katlama, C.; Brun-Vezinet, F.; Calvez, V. 2001: Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy Antiviral Therapy 6(3): 179-183
Balzarini, J.; Velazquez, S.; San-Felix, A.; Karlsson, A.; Perez-Perez, M.J.; Camarasa, M.J.; De Clercq, E. 1993: Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues Molecular Pharmacology 43(1): 109-114
Tambussi, G.; Boeri, E.; Carrera, P.; Gianotti, N.; Lazzarin, A. 1998: Prevalence of mutation associated to resistance with nucleoside analogues in a cohort of naïve HIV-1 positive subjects during the period 1984-1997 Journal of Biological Regulators and Homeostatic Agents 12(1-2 (Suppl): 32-34